These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9836677)

  • 21. Cost effectiveness of coronary heart disease prevention strategies in adults.
    Brown AD; Garber AM
    Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Atheroscler Suppl; 2004 Oct; 5(3):115-23. PubMed ID: 15531284
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost effectiveness of statins.
    Wierzbicki AS; Reynolds TM
    Heart; 2000 Jun; 83(6):713-4. PubMed ID: 10885942
    [No Abstract]   [Full Text] [Related]  

  • 24. Implications of 4S evidence on baseline lipid levels.
    Jacobson TA
    Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245
    [No Abstract]   [Full Text] [Related]  

  • 25. Fire-and-forget in prevention of coronary heart disease.
    Karpe F; Holman R
    Lancet; 2002 Dec; 360(9349):1984; author reply 1984. PubMed ID: 12493308
    [No Abstract]   [Full Text] [Related]  

  • 26. Lipid-lowering drugs and homocysteine.
    de Lorgeril M; Salen P; Paillard F; Lacan P; Richard G
    Lancet; 1999 Jan; 353(9148):209-10. PubMed ID: 9923885
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. After the meta-analyses: a commentary on treatment of dyslipidaemia in the primary prevention of coronary heart disease.
    Silberberg JS
    Aust N Z J Med; 1994 Dec; 24(6):717-21. PubMed ID: 7717926
    [No Abstract]   [Full Text] [Related]  

  • 29. Implications of 4S evidence on baseline lipid levels.
    Durrington PN
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7661979
    [No Abstract]   [Full Text] [Related]  

  • 30. National service framework for coronary heart disease. Ambiguities need to be clarified.
    Lloyd-Mostyn R
    BMJ; 2000 Sep; 321(7261):634. PubMed ID: 11023318
    [No Abstract]   [Full Text] [Related]  

  • 31. Gas chromatography analysis of serum cholesterol synthesis and absorption markers used to predict the efficacy of simvastatin in patients with coronary heart disease.
    Wu WF; Wang QH; Zhang T; Mi SH; Liu Y; Wang LY
    Clin Biochem; 2013 Aug; 46(12):993-998. PubMed ID: 23598259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review.
    McAlister FA; Lawson FM; Teo KK; Armstrong PW
    BMJ; 2001 Oct; 323(7319):957-62. PubMed ID: 11679383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
    Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
    CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary prevention of coronary disease with lipid-lowering drugs.
    Lancet; 1989 Mar; 1(8636):473-4. PubMed ID: 2563844
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of lifestyle changes on coronary heart disease.
    Lear SA
    JAMA; 1999 Jul; 282(2):131-2. PubMed ID: 10411186
    [No Abstract]   [Full Text] [Related]  

  • 36. Primary prevention of ischaemic heart disease with lipid-lowering drugs.
    Lancet; 1988 Feb; 1(8581):333-4. PubMed ID: 2893141
    [No Abstract]   [Full Text] [Related]  

  • 37. Statins in the prevention of coronary heart disease.
    Williamson DR; Pharand C
    Pharmacotherapy; 1998; 18(2):242-54. PubMed ID: 9545143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipids: new guidelines, intensive treatment, and future directions.
    Jones PH
    Tex Heart Inst J; 2006; 33(2):180-3. PubMed ID: 16878620
    [No Abstract]   [Full Text] [Related]  

  • 39. Lipid lowering drugs and coronary heart disease.
    Scott PJ
    Drugs; 1975; 10(3):218-25. PubMed ID: 1104340
    [No Abstract]   [Full Text] [Related]  

  • 40. Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration.
    MacDonald TM; Butler R; Newton RW; Morris AD
    Diabet Med; 1998 Apr; 15(4):282-9. PubMed ID: 9585392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.